Skip to main content
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 2013 Mar 22;124(2):127–129. doi: 10.1007/s004320050144

Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon α2a

U Wollina 1
PMCID: PMC12201678  PMID: 9654196

Abstract

Primary B cell lymphomas of the skin are rare disorders and therapy is not yet standardized. A 45-year-old male patient presented 4 years after surgical removal of a subcutaneous tumour of the leg. On examination a reddish nodular tumour was found in the same region. The biopsy revealed a T-cell-rich primary B cell lymphoma of the skin. Interferon α2a was given perilesionally at a dosage of 9 MU three times a week. The treatment was well tolerated, had no severe side-effects and induced a complete remission, both clinically and histologically, during a 12-months course.

Keywords: Key words Primary cutaneous B cell lymphoma, Interferon α2a, Complete remission

Footnotes

Received: 2 December 1997 / Accepted: 9 December 1997


Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES